Cancer patients value communication, relationships over technical aspects of care

Cancer patients are more concerned with communication and relationships with physicians than the technical aspects of their care, according to a study published in The Joint Commission Journal on Quality and Patient Safety.

Data on what most concerns cancer patients is lacking. In response, researchers evaluated complaints related to cancer care made to the Patient/Family Relations Office at Dana-Farber Cancer Institute in Boston. Complaints were collected from thoughout 2013 and 2014 with the aim to provide a better understanding of patient experiences in care and where improvements could be made.

Overall, 78,668 outpatients filed 266 complaints. Nearly half (48 percent) of the complaints mentioned management issues, 10 percent involved finance and billing, 15 percent focues on service issues, 13 percent on delays and 6 percent on access and admission. Some 41 percent of complaints covered relationships included 15 percent on communication breakdown, patient-staff dialogue (5 percent), and humanness and caring (18 percent).

“Most of the concerns represented in the complaints related to humanistic rather than technical aspects of care,” concluded first author Jennifer W. Mack, MD, MPH, and colleagues. “A systematic review of complaints would offer the opportunity to improve patient-centeredness of care by identifying areas where care fails to meet patient and family needs.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.